Genetics of diffuse large b-cell lymphoma: Paving a path to personalized medicine

Rebecca L. King, Adam Bagg

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Diffuse large B-cell lymphoma, the most common type of lymphoma in Western countries, remains incurable in approximately 40% of patients. Over the past decade, nascent molecular technologies have led to the discovery of many of the genetic events underlying the pathogenesis of this group of diseases. Whether by defining gene signatures that subclassify diffuse large B-cell lymphoma into subgroups, dysregulation of key cellular pathways, or specific mutations, we are approaching an era in which personalized diagnostics, prognostication, and therapy are imminent.

Original languageEnglish (US)
Pages (from-to)43-47
Number of pages5
JournalCancer Journal (United States)
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2014

Keywords

  • Diffuse large B-cell lymphoma
  • nascent molecular technologies
  • personalized diagnostics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Genetics of diffuse large b-cell lymphoma: Paving a path to personalized medicine'. Together they form a unique fingerprint.

Cite this